ThromboGenics and BioInvent announce the start of new study of novel antibody anti-cancer agent TB-403 (Anti-PlGF) by partner Roche
18 May 2011 | By ThromboGenics NV / BioInvent International AB
Two new studies now ongoing...
List view / Grid view
18 May 2011 | By ThromboGenics NV / BioInvent International AB
Two new studies now ongoing...
17 May 2011 | By Merck
Merck announced that it has entered into agreements with Roche...
11 May 2011 | By Fleming Europe
Network with c-level industry leaders from AstraZeneca, Sanofi Aventis, Roche, Novartis, Baxter, Pfizer & Abbott...
20 April 2011 | By Roche
Roche announced that the FDA has approved the cobas HPV (Human Papillomavirus) Test...
19 April 2011 | By Biogen Idec
Genentech, and Biogen Idec announced today that the FDA approved Rituxan® (rituximab)...
Lonza (SIX Swiss Exchange: LONN) and Roche (SWX: ROG) announced today that they have entered into a co-exclusive distribution agreement for the commercialization of Roche’s MycoTOOL® mycoplasma Polymerase Chain Reaction (PCR) assays.
7 April 2011 | By Roche
Roche announced topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer...
21 March 2011 | By Roche
Roche today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results...
17 March 2011 | By GDS International
Personalised medicine is making a comeback – but will it stick this time?...
2 March 2011 | By Roche
Avastin in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe...
21 February 2011 | By Roche
Role will focus on disorders such as schizophrenia, neurodegeneration, treatment-resistant depression & neurodevelopment...
16 February 2011 | By Roche
The phase III study will investigate a subcutaneous formulation of MabThera for patients with non-Hodgkin’s lymphoma...
14 February 2011 | By GDS International
What are the strategies for reducing drug attrition rates in the clinic through the application of transgenic rodent models?...
31 January 2011 | By Roche
Roche announced that the U.S. FDA approved Rituxan/MabThera as a maintenance treatment for patients with advanced follicular lymphoma...
17 January 2011 | By Roche
Erich Hunziker, Chief Financial Officer, Chief Information Officer and Deputy Head of the Corporate Executive Committee has decided to retire from Roche at the end of March 2011...